Imexpharm

Imexpharm Net Debt / EBITDA

The Net Debt to EBITDA of Imexpharm (IMP.VN) as of Oct 26, 2026 is 0.45. In the previous year, Net Debt to EBITDA was 0.20 — a change of 122.39% (higher).

Net Debt / EBITDA

0.45

YoY

122.39%

Last updated:

Net Debt to EBITDA of Imexpharm is 2025 0.45 . Net Debt to EBITDA of Imexpharm was 2024 0.20 . It decreases by 122.39% higher compared to the previous year.

The Imexpharm Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-1.16 VND
Jan 1, 2019
0.18 VND
Jan 1, 2020
0.48 VND
Jan 1, 2021
1.02 VND
Jan 1, 2022
0.31 VND
Jan 1, 2023
0.13 VND
Jan 1, 2024
0.20 VND
Jan 1, 2025
0.45 VND
The Imexpharm Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.45+122.39%
0.20+60.66%
0.13-59.22%
0.31-69.75%
1.02+113.14%
0.48+172.76%
0.18-115.15%
-1.16-43.91%
-2.07+123.24%
-0.93-45.95%
-1.72-3.96%
-1.79-17.58%
-2.17+74.43%
-1.24-5.13%
-1.31+33.01%
-0.99-12.99%
-1.13-24.24%
-1.50+86.73%
-0.80-39.15%
-1.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Net Debt to EBITDA of Imexpharm is 0.45 in 2025.

Net Debt to EBITDA of Imexpharm changed from 0.20 to 0.45, representing a 122.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Imexpharm

All Key Metrics — Imexpharm